Ph3 MK2870 with or without pembro in HR+ HER2 metastatic breast cancer

Phase III Clinical Trial

An Open-label Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician's Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Indication: Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer
Trial Number: 06312176
Trial Status: OPEN

Learn more about this clinical trial.

Participating Locations